Literature DB >> 18600446

Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status.

William D Foulkes1, Matthew J Grainge, Emad A Rakha, Andrew R Green, Ian O Ellis.   

Abstract

Larger breast tumors tend to be associated with a greater number of axillary lymph nodes involved with metastatic tumor than are smaller tumors. This rule may not fully apply in BRCA1-related breast cancers. We hypothesized that the rule also might not apply in basal-like breast cancers (BLBC), and further, that disruption of this relationship would impact on prognosis. In 1,324 non-BLBC (87.1% of 1520 tumors), after adjustment for grade, a strongly positive correlation between increasing tumor size and increasing number of lymph nodes involved by tumor was observed (P for trend <.001). The correlation was much weaker in 196 BLBC (12.9%) (P for trend = 0.58). Similarly, a worsening breast cancer-specific survival with increasing tumor size was observed in non-BLBC (P for trend <.001) but not in BLBC (P for trend = 0.43). The "size-nodes" relationship in BLBC is distinct and is similar to that seen in BRCA1-related breast cancer, further suggesting biological similarities between these sub-types of breast cancer. Moreover, tumor size is not a strong indicator of prognosis in BLBC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600446     DOI: 10.1007/s10549-008-0102-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  27 in total

1.  Triple-negative and basal-like breast cancer: implications for oncologists.

Authors:  J Lachapelle; W D Foulkes
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

2.  Size surprise? Tumour size, nodal status, and outcome after breast cancer.

Authors:  W D Foulkes
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

3.  Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.

Authors:  Bassam S Abdulkarim; Julie Cuartero; John Hanson; Jean Deschênes; David Lesniak; Siham Sabri
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Authors:  Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 5.  Intensified surveillance for early detection of breast cancer in high-risk patients.

Authors:  Ulrich Bick
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

6.  Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.

Authors:  S Subramaniam; N Bhoo-Pathy; N A Taib; G H Tan; M H See; S Jamaris; G F Ho; L M Looi; C H Yip
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

7.  Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

Authors:  Katie M O'Brien; Stephen R Cole; Chiu-Kit Tse; Charles M Perou; Lisa A Carey; William D Foulkes; Lynn G Dressler; Joseph Geradts; Robert C Millikan
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

8.  Behaviour of breast cancer molecular subtypes through tumour progression.

Authors:  Carlos A Castaneda; Eva Andrés; Carmen Barcena; Henry L Gómez; Hernán Cortés-Funés; Eva Ciruelos
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

Review 9.  Tumor size and survival in breast cancer--a reappraisal.

Authors:  William D Foulkes; Jorge S Reis-Filho; Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2010-03-23       Impact factor: 66.675

10.  Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy.

Authors:  Lynn T Dengel; Kimberly J Van Zee; Tari A King; Michelle Stempel; Hiram S Cody; Mahmoud El-Tamer; Mary L Gemignani; Lisa M Sclafani; Virgilio S Sacchini; Alexandra S Heerdt; George Plitas; Manuela Junqueira; Deborah Capko; Sujata Patil; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2013-08-22       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.